Authors
Latest:
Congress, Have a More Thoughtful, Bipartisan Pandemic Post-MortemCongress and our nation’s public health officials should take the current moment to self-reflect and resolve challenges with public confidence in our public and scientific institutions.
Latest:
Succession Attack Plan: Get Strategic with Your Critical RolesOutlining four considerations for biopharma companies in ensuring that their approach to replacing and filling key leadership positions is more truly aligned with future goals in business delivery and risk management.
Latest:
Beyond the Scrubs: Understanding Healthcare Providers as People for Increased EngagementThe benefits of adopting a humanized approach to healthcare provider marketing extend across the healthcare spectrum, enhancing engagement rates, brand loyalty, and marketing ROI, while also driving better outcomes for patients.
Latest:
Why Culture, Ethics, and Compliance Are More Important Than Ever Post-COVIDIf the COVID-19 crisis represents an unprecedented opportunity for pharma to strengthen its public reputation, it also poses enormous risks if things go wrong, writes Professor Guido Palazzo.
Latest:
FDA’s Guidance on Using RWD in Evidence Generation Is a Big Step ForwardPractices to ensure accuracy in selected datasets.
Latest:
Addressing 4 Common Roadblocks When Using RWD in Regulatory SubmissionsScott Swain details the most common roadblocks that pharma companies experience when incorporating real-world data (RWD) in regulatory submissions and looks at how they can be addressed.
Latest:
Value Creation Through Portfolio-Based Corporate StrategyLooking at corporate value through a portfolio lens provides an astute and reliable path to genuine value creation.
Latest:
Breaking OrbitHow pharmaceutical leaders at established companies can still disrupt the status quo and change the game.
Latest:
Patient Services Are Simplifying the Healthcare Consumer ExperienceGrowing business segment of life sciences industry improves patient access.
Latest:
How Can Pharma Companies Join the Digital Therapeutics Revolution?More and more companies are joining forces with software developers to create innovative products. But many are learning the hard way that making next-generation digital therapeutics isn’t as easy as signing a partnership agreement.
Latest:
China’s 2022 NRDL ReadoutDespite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.
Latest:
It’s Time to Get Creative Hiring in a Post-Brexit European Life Sciences MarketBrexit and the pandemic continue to complicate flow of international talent.
Latest:
Digital Automation Becomes Reality in the Life SciencesDigital transformation is no stranger in the life sciences industry.
Latest:
Build Brand Trust with Communities of Color Beyond COVIDWhen it comes to vaccine hesitancy or reluctance, there have always been concerns around the public's belief and attitude. This is especially apparent among blacks and other minority groups, whose concerns can stem from historic injustices that fueled mistrust. The COVID era has presented an opportunity to convert many who are ready to engage via transparency and by initiating trust through marketing.
Latest:
The Transformative Potential of AI in the Pharmaceutical Industry: Opportunities and CautionsThe technology provides the industry with many opportunities, but it must also navigate a complex regulatory landscape.
Latest:
High ImpactAs coverage in Pharmaceutical Executive’s March issue reinforces, AI's connections and permutations are seemingly touching all parts of the industry—and only growing.
Latest:
China 2021: The NRDL ReadoutChina‘s 2021 National Reimbursement Drug List (NRDL) results are finally out, and this year features another major expansion of the NRDL formulary, with ongoing emphasis on innovations and some much anticipated breakthroughs in rare disease drug inclusions.
Latest:
New Bespoke Gene Therapy Consortium Is Welcome DevelopmentFor biopharma innovation to succeed and accelerate, companies must stop duplicating their efforts and share valuable information.
Latest:
Why Pharma Should Develop a Core Digital OfferingHow can pharma create solutions that are effective, can provide long-term value, and will actually be adopted by HCPs and patients?
Latest:
Rx Power Struggle: How Pharma can Flip the PBM ScriptThe industry holds the key to true change to the drug access landscape.
Latest:
Orphan Drugs: From Niche to MainstreamLarger pipeline and increased support from regulatory authorities are setting up the orphan drug market for long-term success.
Latest:
Elevate and De-Risk Your Drug Portfolio Strategy With AIWebinar Date/Time: Wed, Aug 28, 2024 11:00 AM EDT
Latest:
Making the Grade: Registries as Sources of Regulatory-Grade RWEDr Peter Wahl, MLA, MS, Global Head of Scientific Affairs at CorEvitas, part of the PPD clinical research business of Thermo Fisher Scientific, covers key considerations for choosing registries.
Latest:
[Sponsored Content] Patient Engagement Throughout the Entire Product LifecycleIn the pharmaceutical industry, patient engagement should be centered in health education, communication, and strategy during drug discovery and throughout the product lifecycle. Cheryl Lubbert, CEO of Reverba, discusses the importance of a patient-first mindset in the industry.
Latest:
Personalizing Pharma: Overcoming Challenges to Drive Digital Customer EngagementAs HCPs continue to face time constraints and information overload, delivering relevant and personalized content becomes increasingly critical.
Latest:
HEOR: From Proving Product Value to Proving Its Own WorthThe recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.
Latest:
A Risk-Reward Reset: Getting Serious About Social MediaAs the digital medium poses new threats to brand equity and public safety for pharma, what can drugmakers do to better balance its essential communications benefits with the risks?
Latest:
The Real Cost of State Drug Importation Programs? Patient SafetyImporting drugs from Canada may increase the risk of US citizens being exposed to unsafe medicines.
